Positive Phase 1b Results Demonstrate Clinical Proof-of-Concept for ALKS 7290 in Adults With ADHD
Psychiatric Times
A Phase 1b trial showed that ALKS 7290, a novel treatment for ADHD, demonstrated clinical proof-of-concept with positive results in adults. The drug exhibited a favorable safety profile and produced significant improvements in ADHD symptoms. These findings support further development of ALKS 7290 as a potential new therapeutic option.
All articles from 23 September 2026. Summaries are AI-generated and may contain errors; the linked article is the authority.